Payment overview · 2025
General Payments
$842.83
35 reported records · 11 companies
Healthcare provider profile · identity verified
Andrew Imparato, M.D
Allopathic & Osteopathic Physicians|Family Medicine · FULLERTON, CA · NPI 1720400971
Verified facts
What the public records show
CMS Open Payments records show Andrew Imparato, M.D received $842.83 in general payments during 2025 across 35 reported records.
Amgen Inc. accounted for 53.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Paxlovid.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 853 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Austedo Xr by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $452.52 | 53.7% | 20 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.74 | 11.9% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $87.49 | 10.4% | 1 | 2025 |
| Acella Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $55.97 | 6.6% | 3 | 2025 |
| Arcutis Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $24.78 | 2.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.96 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.17 | 2.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $20.34 | 2.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.26 | 2.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.94 | 2.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.66 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $755.34 | 34 |
| Education | $87.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $297.41 | 9 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $155.11 | 11 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $155.11 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $75.86 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.86 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $63.88 | 3 | 2025 |
Source payment records
|
|||||
| NP Thyroid 60 Normalized: np thyroid 60 |
Drug | Acella Pharmaceuticals, LLC | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $24.88 | 1 | 2025 |
Source payment records
|
|||||
| Zoryve Normalized: zoryve |
Drug | Arcutis Biotherapeutics, Inc. | $24.78 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.96 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.94 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 16 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
853 | 104 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO XR open payments reported associated product |
CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228 |
Austedo Xr · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 853 | 104 |
| Atorvastatin Calcium | Atorvastatin Calcium | 839 | 183 |
| Levothyroxine Sodium | Levothyroxine Sodium | 692 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 580 | 120 |
| Famotidine | Famotidine | 443 | 91 |
| Gabapentin | Gabapentin | 408 | 85 |
| Metoprolol Tartrate | Metoprolol Tartrate | 362 | 84 |
| Tamsulosin Hcl | Tamsulosin Hcl | 349 | 86 |
| Furosemide | Furosemide | 327 | 95 |
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 87 |
| Donepezil Hcl | Donepezil Hcl | 274 | 55 |
| Losartan Potassium | Losartan Potassium | 261 | 62 |
| Metformin Hcl | Metformin Hcl | 253 | 65 |
| Olanzapine | Olanzapine | 246 | 49 |
| Mirtazapine | Mirtazapine | 245 | 60 |
| Potassium Chloride | Potassium Chloride | 239 | 58 |
| Memantine Hcl | Memantine Hcl | 233 | 43 |
| Quetiapine Fumarate | Quetiapine Fumarate | 231 | 44 |
| Lisinopril | Lisinopril | 230 | 57 |
| Omeprazole | Omeprazole | 228 | 52 |
| Finasteride | Finasteride | 208 | 35 |
| Xarelto | Rivaroxaban | 202 | 22 |
| Levetiracetam | Levetiracetam | 198 | 31 |
| Hydralazine Hcl | Hydralazine Hcl | 174 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 37 |
| Carvedilol | Carvedilol | 159 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 158 | 36 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 154 | 68 |
| Allopurinol | Allopurinol | 153 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 38 |
| Simvastatin | Simvastatin | 139 | 30 |
| Trazodone Hcl | Trazodone Hcl | 124 | 34 |
| Montelukast Sodium | Montelukast Sodium | 123 | 32 |
| Sertraline Hcl | Sertraline Hcl | 117 | 28 |
| Amiodarone Hcl | Amiodarone Hcl | 116 | 25 |
| Divalproex Sodium | Divalproex Sodium | 113 | 25 |
| Sodium Chloride | 0.9 % Sodium Chloride | 102 | 43 |
| Midodrine Hcl | Midodrine Hcl | 99 | 32 |
| Baclofen | Baclofen | 96 | 21 |
| Lorazepam | Lorazepam | 95 | 41 |
| Latanoprost | Latanoprost | 91 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 91 | 37 |
| Digoxin | Digoxin | 90 | 13 |
| Prednisone | Prednisone | 90 | 33 |
| Lactulose | Lactulose | 87 | 27 |
| Risperidone | Risperidone | 87 | 21 |
| Alendronate Sodium | Alendronate Sodium | 84 | 21 |
| Tramadol Hcl | Tramadol Hcl | 81 | 35 |
| Sucralfate | Sucralfate | 79 | 16 |
| Clonidine Hcl | Clonidine Hcl | 78 | 26 |
| Glipizide | Glipizide | 71 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 68 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 67 | 14 |
| Humulin R | Insulin Regular, Human | 66 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 66 | 29 |
| Januvia | Sitagliptin Phosphate | 65 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 63 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 59 | 45 |
| Primidone | Primidone | 58 | suppressed |
| Spironolactone | Spironolactone | 58 | 22 |
| Atenolol | Atenolol | 57 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 24 |
| Temazepam | Temazepam | 52 | suppressed |
| Aripiprazole | Aripiprazole | 50 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 50 | 40 |
| Lidocaine | Lidocaine | 49 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 45 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 45 | 19 |
| Ertapenem | Ertapenem Sodium | 45 | 12 |
| Methocarbamol | Methocarbamol | 44 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 43 | 23 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Lansoprazole | Lansoprazole | 42 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 42 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 41 | 21 |
| Celecoxib | Celecoxib | 40 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 40 | suppressed |
| Nifedipine Er | Nifedipine | 40 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 21 |
| Torsemide | Torsemide | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 36 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 17 |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 36 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 36 | suppressed |
| Enulose | Lactulose | 35 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 35 | suppressed |
| Bumetanide | Bumetanide | 34 | 12 |
| Metoclopramide Hcl | Metoclopramide Hcl | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 27 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 33 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 32 | 12 |
| Ingrezza | Valbenazine Tosylate | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 26 |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | suppressed |
| Azithromycin | Azithromycin | 31 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 14 |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 30 | 14 |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Xifaxan | Rifaximin | 30 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 29 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 11 |
| Pregabalin | Pregabalin | 28 | suppressed |
| Budesonide | Budesonide | 27 | 12 |
| Folic Acid | Folic Acid | 27 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 27 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 27 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 26 | suppressed |
| Calcitriol | Calcitriol | 26 | suppressed |
| Myrbetriq | Mirabegron | 26 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 26 | suppressed |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Metolazone | Metolazone | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 24 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 20 |
| Clonazepam | Clonazepam | 22 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 22 | suppressed |
| Humalog | Insulin Lispro | 22 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 13 |
| Scopolamine | Scopolamine | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 20 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 15 |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Valproic Acid | Valproic Acid | 19 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Sodium Chloride | Sodium Chloride Irrig Solution | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Novolin R | Insulin Regular, Human | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 15 | 11 |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 15 | suppressed |
| Dutasteride | Dutasteride | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Nystop | Nystatin | 15 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 15 | 15 |
| Valsartan | Valsartan | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Sotalol | Sotalol Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Austedo Xr | Deutetrabenazine | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Donepezil Hcl Odt | Donepezil Hcl | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Admelog | Insulin Lispro | 12 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acetylcysteine | Acetylcysteine | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | 11 |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $842.83 · 35 records | Amgen Inc. | AIRSUPRA, Cologuard Collection Kit, EVENITY, JARDIANCE, KISUNLA, LEQVIO, MOUNJARO, NP Thyroid 60, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PROLIA, REPATHA, Rybelsus, ZEPBOUND, Zoryve | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error